Your browser doesn't support javascript.
loading
Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021.
Luo, Xingxian; Du, Xin; Li, Zhuangqi; Qian, Feng; Yang, Yue.
Afiliación
  • Luo X; School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
  • Du X; Key Laboratory of Innovative Drug Research and Evaluation, National Medical Products Administration, Beijing, China.
  • Li Z; Tsinghua-Peking Center for Life Sciences, Beijing, China.
  • Qian F; School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
  • Yang Y; Key Laboratory of Innovative Drug Research and Evaluation, National Medical Products Administration, Beijing, China.
Clin Pharmacol Ther ; 113(1): 170-181, 2023 01.
Article en En | MEDLINE | ID: mdl-36151921
Access to anticancer drugs has been a critical health issue in China for many years. We retrospectively analyzed the novel anticancer drugs approved in the United States (US) between 2010 and 2021 to assess the evolving landscape of the drug lags in China by taking Japan and the European Union (EU) as comparisons. The absolute and relative lags of drug initial approval (DIA) and indication approval were calculated between China (or Japan/European Union) and the US based on the US approval date of novel agents, the duration was divided into 2010-2015 and 2016-2021. Overall, 123 (244 indications) new molecular entities (NMEs) approved in the United States were included, of which 58 (94 indications), 72 (128 indications), and 99 (170 indications) NMEs were also approved in China, Japan, and the European Union, respectively. The absolute lags of DIA and indications for approval in China improved dramatically in 2016-2021 compared with 2010-2015. Similarly, the relative DIA and indication approval lags in China decreased significantly in 2016-2021. The median review lags for DIA of China in 2016-2021 were comparable to Japan but dramatically lower than that of the European Union. Nevertheless, China had significantly longer median submission lags for DIA (28 months) in 2016-2021 than that of Japan (6 months) and the European Union (1 month). Although the absolute and relative lags of anticancer drugs in China had been initially addressed, 53% of NMEs and 61% of indications were still not approved for cancers in China compared with the United States. Therefore, China should adopt steps to further reduce drug lags.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Límite: Humans País/Región como asunto: America do norte / Asia Idioma: En Revista: Clin Pharmacol Ther Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Límite: Humans País/Región como asunto: America do norte / Asia Idioma: En Revista: Clin Pharmacol Ther Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos